Get the Stockscreener App
6.69
17.85%
1.0132
After Hours:
6.90
0.21
+3.14%
Sonnet Biotherapeutics Holdings Inc stock is traded at $6.69, with a volume of 49,317.
It is up +17.85% in the last 24 hours and up +15.98% over the past month.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
See More
Previous Close:
$5.6768
Open:
$5.54
24h Volume:
49,317
Relative Volume:
2.94
Market Cap:
$34.80M
Revenue:
$129.20K
Net Income/Loss:
$-14.46M
P/E Ratio:
-0.1034
EPS:
-64.68
Net Cash Flow:
$-18.52M
1W Performance:
-11.40%
1M Performance:
+15.98%
6M Performance:
-55.04%
1Y Performance:
-70.81%
1-Day Range:
$5.53
$6.79
1-Week Range:
$5.4392
$7.44
52-Week Range:
$4.9912
$23.44
Sonnet Biotherapeutics Holdings Inc Stock (SONN) Company Profile
Name
Sonnet Biotherapeutics Holdings Inc
Sector
Industry
Phone
609-375-2227
Address
100 OVERLOOK CENTER, PRINCETON, NJ
Sonnet Biotherapeutics Holdings Inc Stock (SONN) Latest News
Sonnet BioTherapeutics enacts reverse stock split By Investing.com - Investing.com Canada
Sonnet BioTherapeutics enacts reverse stock split - Investing.com India
Sonnet BioTherapeutics announces launch of CEO Corner platform - TipRanks
Sonnet BioTherapeutics Announces Launch of CEO Corner Platform - GlobeNewswire
Sonnet BioTherapeutics Announces Launch of CEO Corner Platform - StockTitan
Why Telesis Bio Shares Are Trading Higher By Around 110%; Here Are 20 Stocks Moving Premarket - Benzinga
Sonnet BioTherapeutics enacts 1-for-8 reverse stock split By Investing.com - Investing.com South Africa
Why Sonnet BioTherapeutics (SONN) Shares Are Down 19% Today - Benzinga
Sonnet BioTherapeutics enacts 1-for-8 reverse stock split By Investing.com - Investing.com Australia
Sonnet BioTherapeutics enacts 1-for-8 reverse stock split - Investing.com India
Sonnet BioTherapeutics enacts 1-for-8 reverse stock split By Investing.com - Investing.com Canada
Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split - citybiz
Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split - StockTitan
Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split - GlobeNewswire
Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split - Yahoo Finance
Financial Contrast: Telomir Pharmaceuticals (NASDAQ:TELO) & Sonnet BioTherapeutics (NASDAQ:SONN) - Defense World
Sonnet BioTherapeutics Completes Enrollment in Phase 1 - GlobeNewswire
Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors - StockTitan
Sonnet BioTherapeutics (NASDAQ:SONN) Stock Quotes, Forecast and News Summary - Benzinga
Sonnet BioTherapeutics shareholders approve key proposals - Investing.com
Sonnet BioTherapeutics shareholders approve key proposals By Investing.com - Investing.com Canada
Sonnet BioTherapeutics to Present at Investor Series - TipRanks
Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series - ForexTV.com
Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series - StockTitan
Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series - GlobeNewswire
Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series - Yahoo Finance
Sonnet BioTherapeutics gets extension to meet Nasdaq rule - Investing.com
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) Short Interest Update - Defense World
Sonnet BioTherapeutics (NASDAQ:SONN) Given “Buy” Rating at Chardan Capital - Defense World
Holdings of Sonnet BioTherapeutics Holdings Inc (SONN) are aligned with the stars - SETE News
Are Sonnet BioTherapeutics Holdings Inc’shares a good deal? - US Post News
Daily Progress: Sonnet BioTherapeutics Holdings Inc (SONN) Drop -18.83, Closing at 0.66 - The Dwinnex
Sonnet BioTherapeutics advances pancreatic cancer treatment - Investing.com
Sonnet BioTherapeutics Enters into Clinical Collaboration - GlobeNewswire
Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer - Yahoo Finance
why Sonnet BioTherapeutics Holdings Inc [SONN] is a Good Choice for Investors After New Price Target of $14.67 - The DBT News
Company’s Banking Shares: Up -91.97% from 52-Week Low, But Can the Momentum Hold? - The InvestChronicle
Sonnet BioTherapeutics (NASDAQ:SONN) Announces Earnings Results - Defense World
Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update - StockTitan
SONN stock touches 52-week low at $0.71 amid market challenges - Investing.com Australia
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) Short Interest Up 168.1% in July - Defense World
SONN stock touches 52-week low at $0.71 amid market challenges - Investing.com
SONN stock touches 52-week low at $0.76 amid market challenges - Investing.com
Best Biotech Penny Stocks Right Now • Updated Daily - Benzinga
Can you still get a good price for Sonnet BioTherapeutics Holdings Inc (SONN) Shares at this point? - US Post News
Sonnet BioTherapeutics (NASDAQ:SONN) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team - Yahoo Finance
Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study - ForexTV.com
Sonnet BioTherapeutics Reports Encouraging Data from Phase - GlobeNewswire
Sonnet BioTherapeutics (NASDAQ:SONN) Shares Down 1.1% - Defense World
Sonnet BioTherapeutics files to sell 5.77M shares of common stock for holders (SONN) - Seeking Alpha
Sonnet Biotherapeutics Holdings Inc Stock (SONN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):